Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Discounted Cash Flow Valuation of Merck & Co., Inc.
In the chart Earnings are multiplied by this value.
High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.
The average Net Margin over the past 5 years is +17.92%.
The trend of Net Margin over the past 5 years is +3.51%.
The average ROA over the past 5 years is +11.55%.
The trend of ROA over the past 5 years is +1.2%.
The average ROE over the past 5 years is +26.84%.
The trend of ROE over the past 5 years is +4.18%.
Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.
The Debt/FCF trailing twelve month is 2.65.
The trend of Debt/FCF over the past 5 years is -0.31.
Graham’s Stability measure stands at 0.35.
Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.
The Revenue CAGR over the past 5 years is +8.12%.
The trend of Revenue growth rate over the past 5 years is +2.34%.
The Earnings CAGR over the past 5 years is +43.4%.
The trend of Earnings growth rate over the past 5 years is -2.18%.
The Equity CAGR over the past 5 years is +5.91%.
The trend of Equity growth rate over the past 5 years is +5.19%.
The FCF CAGR over the past 5 years is +26.4%.
The trend of FCF growth rate over the past 5 years is +6.64%.